Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Primary Target | Pathway | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|---|---|
| SUM159PT | Cediranib | 10.0 | VEGFR/cKIT | RTK | 0.3173 | 0.07979 |
| SUM159PT | Cabozantinib | 0.001 | VEGFR2/MET | RTK | 1.0020 | 0.00108 |
| SUM159PT | Cabozantinib | 0.0031623 | VEGFR2/MET | RTK | 1.0067 | -0.00025 |
| SUM159PT | Cabozantinib | 0.01 | VEGFR2/MET | RTK | 1.0155 | 0.00176 |
| SUM159PT | Cabozantinib | 0.031623 | VEGFR2/MET | RTK | 1.0024 | -0.00116 |
| SUM159PT | Cabozantinib | 0.1 | VEGFR2/MET | RTK | 1.0115 | -0.00152 |
| SUM159PT | Cabozantinib | 0.31623 | VEGFR2/MET | RTK | 0.9965 | 0.00568 |
| SUM159PT | Cabozantinib | 1.0 | VEGFR2/MET | RTK | 0.9307 | 0.03130 |
| SUM159PT | Cabozantinib | 3.1623 | VEGFR2/MET | RTK | 0.7480 | 0.08743 |
| SUM159PT | Cabozantinib | 10.0 | VEGFR2/MET | RTK | 0.1744 | 0.19675 |